OncRef

Clinical Trial: NCT06539195

DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9)

Status:

COMPLETED

Phase:

Phase 2

Lead Sponsor:Dizal Pharmaceuticals
Information Provided By:Dizal Pharmaceuticals
Last Update Posted:2026-08-04

Study Overview

Brief Summary

This study will treat patients with DLBCL whose disease comes back or is not responding to prior therapy. This study will assess the anti-tumor activity of DZD8586 as monotherapy. It will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body.

Official Title

A Phase 2, Open-label, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Conditions

Diffuse Large B Cell Lymphoma

Intervention / Treatment

  • Drug: DZD8586
  • Drug: DZD8586
  • Drug: DZD8586

Other Study ID Numbers

  • DZ2023B0003

Start Date (Actual)

2024-03-13

Primary Completion Date (Actual)

2026-06-10

Study Completion Date (Actual)

2026-06-10

Enrollment (Actual)

59

Study Type

Interventional

Phase

Phase 2